Core Viewpoint - The shareholders of Pan-Asia Micro-Pore (688386.SH) plan significant share reductions, citing personal funding needs and long-term investment recovery as reasons for the divestment [1][2]. Shareholder Reduction Plan - Shareholders Changzhou Sequoia High-tech Venture Capital Center and Jiangsu Southern Precision Engineering hold 8.36% and 7.34% of the company, respectively, and plan to reduce their holdings by up to 280,000 shares and 210,000 shares, representing 4% and 3% of the total share capital [1]. - The reduction will occur within three months after the announcement, through centralized bidding and block trading [1]. Stock Performance - Since the beginning of the year, the stock price of Pan-Asia Micro-Pore has increased from approximately 28 CNY per share to a peak of 59.49 CNY per share, more than doubling [2]. - As of May 7, the closing price was 54.04 CNY per share, and if the maximum reduction occurs, the shareholders could realize approximately 265 million CNY [2]. Financial Performance - In 2020, the company reported revenues of 278 million CNY and a net profit of 55.27 million CNY, marking year-on-year growth of 13.23% and 26.37% [3]. - In 2021, revenue continued to grow, but net profit decreased by 52.79% in 2022 to 31.34 million CNY despite revenue growth to 364 million CNY [3]. - In 2023, the company reversed its fortunes with revenues of 411 million CNY and a net profit of 86.54 million CNY, reflecting year-on-year growth of 12.64% and 176.08% [3]. - Projections for 2024 indicate further growth, with expected revenues of 515 million CNY and a net profit of 99.16 million CNY, representing increases of 25.39% and 14.58% [3]. Cash Flow and Operational Insights - In Q1 2023, the company reported a negative operating cash flow of -2.83 million CNY, a decline of 118.60% year-on-year [4]. - The increase in net profit is attributed to higher sales of core technology products, including ePTFE micro-pore products and aerogel products, while cash flow issues stem from reduced receivables and increased payroll expenses [4].

和元生物公告，股东华睿盛银及其一致行动人计划减持不超过649.04万股，占公司总股本的1%。减持 期间为2025年5月30日至2025年8月29日，减持方式为集中竞价和大宗交易。 ...

上海新阳（300236）公告，持股5%以上股东上海新科投资有限公司计划在2025年5月29日至2025年8月 28日期间，通过集中竞价或大宗交易方式减持不超过200万股，占公司总股本的0.64%。 ...

春秋航空于2015年1月21日在上海证券交易所上市，发行价格为18.16元/股，发行数量为100,000,000 股，本次发行募集资金总额为1,816,000,000元，扣除发行费用后募集资金净额为1,754,630,200元。发行 总费用为61,369,800元，承销及保荐费用为45,375,000元。保荐人(主承销商)为瑞银证券有限责任公司， 保荐代表人为汤双定、司宏鹏。 三个股东合计拟减持其持有的公司无限售条件流通股不超过7,814,700股(占公司总股本不超过0.80%)。 本次减持自减持计划公告披露日起15个交易日后3个月内进行，且在任意连续90个自然日内，三个股东 及一致行动人合计采取集中竞价交易方式减持股份的总数不超过公司总股本的1%。 中国经济网北京5月8日讯春秋航空（601021）(601021.SH)昨晚发布股东减持股份计划公告。截至公告 披露日，春秋航空股东：(1)上海春秋包机旅行社有限公司(以下简称"春秋包机")持有公司股份 22,720,600股，占公司总股本比例为2.32%；(2)上海春翔投资有限公司(以下简称"春翔投资")持有公司股 份15,785,507股，占公司总股本比例为1 ...

Core Viewpoint - Shenzhen Qianhai Shengtai Investment Enterprise plans to reduce its stake in Chengda Pharmaceutical by up to 4,894,943 shares, representing 3.23% of the company's total share capital, due to the shareholder's operational needs [1][2] Group 1: Shareholder Information - Shenzhen Qianhai Shengtai holds 15,901,840 shares, accounting for 10.50% of the company's total share capital after excluding repurchased shares [1][2] - The planned reduction will occur within three months from May 30, 2025, to August 29, 2025, through block trading [1] - The shareholder is not a controlling shareholder or actual controller of the company, and the reduction will not lead to a change in control or significantly impact the company's governance structure [2] Group 2: Company Financials - Chengda Pharmaceutical's initial public offering raised a total of 1.757 billion yuan, with a net amount of 1.621 billion yuan after deducting issuance costs [3] - The company reported a revenue of 333.13 million yuan in 2024, a decrease of 19.59% compared to 2023 [4][5] - The net profit attributable to shareholders was -28.10 million yuan in 2024, a decline of 130.89% year-on-year [4][5] - For Q1 2025, the company achieved a revenue of 76.31 million yuan, down 24.37% year-on-year, with a net loss of -1.40 million yuan [6]

中新赛克（002912）公告，股东广东红土、昆山红土、南京红土、郑州百瑞合计持有公司股份957.76万 股，占公司总股本比例5.61%。上述股东计划通过集中竞价和大宗交易方式合计减持不超过512.25万 股，占总股本比例3%。减持将在公告披露15个交易日后的3个月内进行，集中竞价减持不超过总股本 1%，大宗交易减持不超过总股本2%。减持原因系创业投资基金退出需求。减持价格将根据市场价格确 定，且不低于公司发行价和最近一期经审计每股净资产。公司控股股东与减持股东为一致行动人。 ...

蓝箭电子（301348）公告，持股5%以上股东上海银圣宇企业管理咨询合伙企业计划在公告披露之日起 15个交易日后的三个月内以集中竞价方式减持不超过200万股，占公司总股本1%。董事、总经理袁凤江 拟减持不超过38.89万股，占公司总股本0.19%。董事、副总经理、财务总监赵秀珍拟减持不超过48.96 万股，占公司总股本0.24%。董事、副总经理、董事会秘书张国光拟减持不超过25.83万股，占公司总股 本0.13%。监事李永新拟减持不超过23.78万股，占公司总股本0.12%。减持原因均为股东自身资金需 求。 ...

中国经济网北京5月7日讯森霸传感（300701）(300701.SZ)昨日晚间披露实际控制人之一致行动人减持计划期限届满暨实施结果的公告。 | 股东名称 | 減持方式 | 减持时间 | 减持均价 | 减持股数 | 减持比例 | | --- | --- | --- | --- | --- | --- | | | | | (元/股) | (股) | (%) | | 康腾 8 号 | 集中竞价交易 | 2025/3/26- | 10.7400- | 521,500 | 0.1844 | | | (含盘后定价) | 2025/3/27 | 10.9400 | | | | 康腾 8 号 | 大宗交易 | 2025/2/20- | 9.4400 - | 1,791,570 | 0.6337 | | | | 2025/4/1 | 10.2800 | | | | N. V.T. | 集中竞价交易 | 2025/2/14- | 10.1100- | | | 森霸传感表示，康腾8号、单颖属于公司实际控制人单森林之一致行动人，减持计划的实施不会导致公司控制权发生变更，也不会对公司的治理结构及持 续经营产生重大影响。 2025年第一 ...

中国经济网北京5月7日讯迦南智能（300880）(300880.SZ)昨日晚间发布关于公司实际控制人之一致行动人减持股份预披露的公告。 公司于近日收到公司实际控制人之一致行动人宁波鼎耀企业管理合伙企业(有限合伙)(以下简称"鼎耀合伙")及公司实际控制人之一致行 动人周小玲、周月芬、周森月、何利荣提交的《关于股份减持计划的告知函》。 公司实际控制人章国耀、章恩友之一致行动人鼎耀合伙(原"宁波杭州湾新区鼎耀企业管理合伙企业(有限合伙)")系公司员工持股平台， 持有公司股份36,007,200股(占本公司总股本比例18.4522%)，计划在公告披露之日起15个交易日后的3个月内以集中竞价方式减持股份 数量不超过1,441,589股，减持比例不超过公司股份总数的0.7388%。 公司实际控制人章国耀、章恩友之亲属周小玲、周月芬、周森月、何利荣，构成公司实际控制人的一致行动人，分别持有公司股份 960,192股、240,048股、120,024股、120,024股，持股比例分别为0.4921%、0.1230%、0.0615%、0.0615%，计划在公告披露之日起15个 交易日后的3个月内以集中竞价方式减持股份数量合计不 ...

Core Points - Gannee Pharmaceutical (甘李药业) announced the completion of a share reduction plan by its shareholder, Beijing Xutong Hongda Technology Co., Ltd. (旭特宏达), which reduced its holdings by 6,010,622 shares, representing 1% of the company's total share capital [1][2] - The share reduction occurred between April 22, 2025, and April 30, 2025, with a price range of 44.85 to 49.81 yuan per share, totaling approximately 290.35 million yuan [1][2] - After the reduction, Xutong Hongda holds 35,473,235 shares, accounting for 5.90% of the total share capital [2] Shareholder Information - Before the reduction, Xutong Hongda and its concerted party, Gan Zhongru, held a combined total of 247,127,614 shares, which is 41.11% of the total share capital [3] - Xutong Hongda owned 41,483,857 shares (6.90%), while Gan Zhongru held 205,643,757 shares (34.21%) [3] - Gan Zhongru is the largest shareholder of Gannee Pharmaceutical, and Xutong Hongda is the second largest [3] Fundraising Activities - Gannee Pharmaceutical went public on June 29, 2020, raising a total of 2.545 billion yuan, with a net amount of 2.441 billion yuan after expenses [4] - The funds raised were allocated for various projects, including marketing network construction and product registration in the U.S. [4] - In 2023, the company issued 28,508,550 shares at a price of 27.12 yuan per share, raising approximately 773.15 million yuan, with a net amount of about 759.73 million yuan after expenses [5]